In a report issued on May 4, Ann Hynes from Mizuho Securities reiterated a Buy rating on CVS Health (CVS – Research Report), with a price target of $115.00. The company’s shares closed last Thursday at $97.73.
According to TipRanks.com, Hynes is a 5-star analyst with an average return of 9.4% and a 59.2% success rate. Hynes covers the Healthcare sector, focusing on stocks such as Molina Healthcare, Acadia Healthcare, and Quest Diagnostics.
Currently, the analyst consensus on CVS Health is a Strong Buy with an average price target of $119.57, representing a 18.8% upside. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a $127.00 price target.
The company has a one-year high of $111.25 and a one-year low of $78.75. Currently, CVS Health has an average volume of 5.68M.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Headquartered in Rhode Island and founded in 1963, CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands.
Read More on CVS:
- Pioneer Natural (PXD) Gets a Buy Rating from Mizuho Securities
- Mizuho Securities Maintains Their Hold Rating on Continental Resources (CLR)
- Mizuho Securities Keeps a Buy Rating on Murphy Oil (MUR)
- Corteva (CTVA) Receives a Buy from Mizuho Securities
- Mizuho Securities Thinks Ceridian HCM Holding’s Stock is Going to Recover